Promising therapeutic agents for sepsis
Authors:
- Mitchell P. FinkMFMitchell P. Fink
- 1 January 2007
- journal article
- review article
- Published by Elsevier in Trends in Microbiology
- Vol. 15 (1) , 31-37
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsisBMC Emergency Medicine, 2005
- Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathNew England Journal of Medicine, 2005
- Challenge and Rechallenge: Drotrecogin alfa (activated)–Induced Prolongation of Activated Partial Thromboplastin Time in a Patient with Severe SepsisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Time Course of Hemostatic Abnormalities in Sepsis and its Relation to OutcomeChest, 1993
- Septic Shock, Multiple Organ Failure, and Disseminated Intravascular CoagulationChest, 1992
- Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.Journal of Clinical Investigation, 1987
- BACILLUS COLI SEPSISJAMA, 1924